- Completed
NCT00574288: Phase 1/2: Daratumumab (HuMax®-CD38) Safety Study in Multiple Myeloma - GEN501 study
Updated: Mar 28, 2022
GEN501 study

Daratumumab (HuMax®-CD38) Safety Study in Multiple Myeloma
Establishment of safety profile of HuMax-CD38 when given as monotherapy in participants with multiple myeloma relapsed from or refractory to at least 2 different cytoreductive therapies and without further established treatment options.
Multiple Locations
International Study
ClinicalTrials.gov Identifier: NCT00574288
Daratumumab : National Cancer Institute
Daratumumab : MedlinePlus Drug Information
Publications:
Lancet Haematol. 2020 Jun;7
Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma.
N Engl J Med. 2015 Sep 24